Bundle Offer from La Merie Publishing
Market Publishers is extremely happy to announce a great discount opportunity on behalf of La Merie Publishing, our Germany-based research partner.
From now all Market Publishers’ customers can become owners of a bundle of market research studies prepared by our partner at a discounted price.
The studies cover:
- Antibody-Drug Conjugates
- Biosimilar and Biosuperior Therapeutic Antibodies
- T-Cell Redirecting Bispecific Antibodies
- Bispecific Antibodies for Cancer, Inflammatory and Other Diseases
Please, find prices for the bundle below:
| License | Price in EUR (€) | Price in USD ($) |
| Single User | 3,100 | 3,500 |
| Site License | 6,200 | 7,000 |
| Global License | 9,300 | 10,500 |
By getting simultaneously all four reports mentioned above you will be given a 50% discount on all license types.
Are you interested in this offer? Do not hesitate any more, send us an email.
... about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the the first wave of biosimilar ... , pavilizumab, tocilizumab, and ustekinumab. Download sample pages of Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update Competitor projects are listed in a tabular format providing information ...
May, 2016 462 pagesCompetitor Analysis: Bispecific Antibodies for Cancer, Inflammatory Other Diseases This Competitive Intelligence report about Bispecific Antibodies for Cancer, Inflammatory Other Diseases evaluates the competitive ... as: T-Cell or NK cell redirecting bispecific cancer antibodies Bispecific immuno-oncology antibodies Bispecific tumor antigens targeted cancer antibodies Bispecific antibodies for inflammatory autoimmune diseases Bispecific antibodies for cardiometabolic, infectious, neurologic ...
Jun, 2016 180 pages... T-cell or natural killer (NK) cells redirecting bispecific antibodies has increased from 4 to 21 and further 16 molecules could enter clinical development within the next 12 months. This report T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals “ as of May 2016 brings you up-to-date information ...
May, 2016 230 pages... same number of ADC programs are in preclinical R&D. Download Samples Pages: Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis For the first ... entitled „Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis“ is based on the analysis of more than 90 companies, more than 100 ADC drug profiles ...
Nov, 2015 470 pages
